Key result
Eptifibatide during PCI linked to acute-onset severe thrombocytopenia in one patient.
Why the study?
Thrombocytopenia is a rare side effect of eptifibatide administration with an unclear mechanism.
Case Report (n=1)
Highlights a rare but severe side effect of eptifibatide, acute-onset severe thrombocytopenia, during percutaneous coronary intervention.
Clinicians should monitor platelet counts with eptifibatide in PCI; single case leaves open questions on true incidence.
Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia. Several case reports have described thrombocytopenia as a rare side effect of eptifibatide administration. The exact mechanism remains unclear but may be due to immune destruction of circulating platelets in the peripheral blood. We present the case of acute-onset severe thrombocytopenia in a 76-year-old female undergoing percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Kamar et al. (2021) conducted a case report in Acute-onset severe thrombocytopenia (n=1). Eptifibatide was evaluated on Acute-onset severe thrombocytopenia. Eptifibatide administration during percutaneous coronary intervention resulted in acute-onset severe thrombocytopenia in 1 76-year-old female patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: